Indaptus Therapeutics (INDP) Projected to Release Earnings on Tuesday

Indaptus Therapeutics (NASDAQ:INDP) is expected to announce its Q3 2026 results before the market opens on Tuesday, November 17th. Analysts expect the company to post earnings of ($1.46) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.57) by $1.55.

Indaptus Therapeutics Stock Down 5.7%

Shares of INDP opened at $3.13 on Tuesday. The firm has a market cap of $417.04 million, a price-to-earnings ratio of -0.49 and a beta of 0.96. The business’s 50 day moving average is $2.80 and its two-hundred day moving average is $2.31. Indaptus Therapeutics has a 52-week low of $0.92 and a 52-week high of $5.96.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Indaptus Therapeutics has a consensus rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the body’s immune system to fight cancer and other serious diseases. The company’s approach is based on using attenuated or inactivated bacterial agents to activate multiple components of the immune response.

Indaptus’ lead product candidate is Decoy20, an investigational, systemically administered bacterial immunotherapy. The treatment is designed to engage innate and adaptive immune pathways and potentially improve the body’s ability to recognize and attack tumor cells.